Organic Active Ingredients TRIZ Cases

Pancreatic tumor treatment faces systemic toxicity and a desmoplasia barrier; coaxial polymer fibres provide controlled, prolonged local drug release.

Hydrolysis-prone amidine bonds are replaced with amide linkages, improving mannose retention and reproducibility in carbohydrate-polymer products.

Selective NaV1.6 compounds inhibit hyperactive neuronal sodium channels to control seizures while limiting neurotoxicity and cognitive effects.

Poorly water-soluble rifabutin is dissolved at high concentration with acid and solvent for parenteral, inhaled, or pulmonary delivery.

Hydrobromide, citrate, maleate, and other salts address Compound 1 solubility and stability limits in oral delivery.

Novel Encequidar crystal forms address handling, stability, and processing needs in formulations combined with Paclitaxel.

Tricyclic cores with pyrrole and amide groups support potent HBV inhibition, better solubility, and improved bioavailability.

A polymer scaffold releases therapeutic agents locally and over time, then bioresorbs within target tissue to limit repeated treatment burden.

Defined quinazoline substitutions tune kinase binding to balance cancer-treatment activity with selectivity across EGFR-mutant targets.

Amorphous nilotinib fumarate or tartrate dispersions with polymer carriers improve fasted-state bioavailability and reduce fed–fasted variability.

STING agonists activate innate immunity while checkpoint inhibitors boost T-cell activity against resistant cancers.

PROTAC compounds recruit E3 ubiquitin ligases to mark BCL6 for proteasomal degradation in cancer and autoimmune disease.

Rocaglamide derivatives block eIF4A-dependent translation to arrest MPNST cells, induce apoptosis, and suppress tumor growth.

Poor solubility and bioavailability limit chronic BK B2 antagonist therapy; a hydrophilic matrix tablet sustains release for at least 10 hours.

See how selective deuteration of MK2 pathway inhibitors improves metabolic stability while molecular tuning supports efficacy and specificity.

Diminazene-based small molecules are screened with biophysical assays to stabilize or destabilize RNA triple helices and probe recognition.

A moisture barrier plus steroid, antifungal, and antibiotic components addresses wetness, inflammation, fungal infection, and bacterial infection in diaper rash.

iPSC-derived megakaryocytes and platelets carry small-molecule or protein therapeutics, addressing donor shortages and limited targeting.

An injectable biodegradable nanogel forms in situ to stabilize drugs and extend release, reducing frequent dosing without surgery.

This case uses reduced, once-daily dextromethorphan–bupropion dosing to limit drug accumulation and adverse effects in renal impairment.

Targeted substituent changes preserve anti-tumor activity while improving camptothecin solubility and chemical stability.

Orally bioavailable ferroportin inhibitors address MDS iron overload and ineffective erythropoiesis while reducing the burden of parenteral treatment.

Hydrostatic pressure drives a cell-killing agent from the necrotic core through hypoxic tissue, while an antidote protects healthy cells.

See how Forms A, B, and C use XRPD and thermal profiles to control solid-state properties affecting BTK drug stability and solubility.

WRN helicase and ATPase inhibition offers a complementary approach for MSI-H/dMMR cancers facing limited checkpoint response and resistance.

By replacing monoclonal antibody mechanisms with chemical compounds, this approach targets PD-1/PD-L1 while reducing therapeutic complexity.

Crystallization of hemihydrate R-mandelate salts helps control impurities and improve consistency in ulotaront HCl manufacturing.

A dCas9-VPR complex activates TTN regulatory regions to restore protein expression across diverse DCM mutations without DNA cleavage.

Novel CRBN ligands vary Formula I substituents and side chains to preserve binding while degrading IKZF, WEE1, and CK1α.

Small-molecule TREM-1 inhibitors address short peptide lifespans while reducing proinflammatory cytokines and inflammatory responses.

These compounds inhibit plasma kallikrein to reduce thrombin generation, support clot dissolution, and limit reocclusion during fibrinolysis.

PLGA microparticles gradually release levothyroxine, extending pharmacological action from daily dosing to one administration lasting up to two months.

This amino acid combination raises plasma histidine and improves antioxidant defense to reduce liver steatosis, inflammation, and fat accumulation.

Drug-resistant RET variants such as G810R and Y806C can reduce inhibitor efficacy; heterocyclic compounds maintain targeted inhibition with favorable PK and safety profiles.

HFO-1234ze(E) and ethanol keep concentrated fluticasone particles dispersed, limiting flocculation and enabling stable single-actuation dosing.

AAK1-targeted compounds address mutation-limited muscular dystrophy therapies by promoting skeletal muscle growth and regeneration.

mPR agonists enhance GABAergic inhibition by increasing GABA receptor expression and phosphorylation to reduce brain excitability.

C19 restores centrosome organization and cardiomyocyte contractility in congenital dilated cardiomyopathy.

Cycloastragenol at 3–500 ng/ml is combined with antimicrobial, chelator, and excipient components to support telomerase activity and corneal tissue viability.

To address weak CDK2/Cyclin A selectivity, the compound tunes pyrazole substituents and ester structure to stall S phase or trigger apoptosis.

PIKfyve inhibitors disrupt lysosome homeostasis and coronavirus membrane trafficking, blocking infection below toxic concentrations in cultured cells.

Small-molecule compounds block SOS1–Ras-family binding, preventing KRas recycling into its active form for SOS1-associated cancer treatment.

See how pilocarpine eye formulations restore near vision through ciliary-muscle action while avoiding cumbersome lenses and surgery.

See how L-NIL-MDP peptide hydrogels replace repeated oral dosing with sustained intratumoral iNOS inhibition from a single injection.

Species-specific CRISPR targeting alters gut microbiota to modulate immune cell therapies while sparing related beneficial strains.

A local injectable blend of dexamethasone and ketorolac controls pain and swelling while reducing postoperative opioid use.

A pH-adjusted cleanser combines antibacterial and anti-inflammatory agents to manage blepharitis while reducing irritation around delicate eyelid skin.

Drug-resistant myeloma cells are targeted with LINC01432 LNA GapmeR inhibitors alongside melphalan to increase apoptosis and chemotherapy efficacy.

Defined heterocyclic rings help BET inhibitors bind selectively and covalently, reducing off-target effects and toxicity in therapy.

Co-crystallizing efinaconazole with pharmaceutically acceptable coformers addresses storage discoloration while supporting stable pharmaceutical formulations.

A fixed dose combination of pramipexole and rasagiline uses extended-release coating layers to deliver controlled drug release over 24 hours.

Optimized hydrolyzable tannoid composition from Terminalia chebula reduces joint inflammation and pain without NSAID side effects.

Hydroxycitric acid boosts ketone utilization, resolving low blood oxygen saturation in Alzheimer's patients through real-time fNIRS monitoring.

Macrocyclic spirocarbamate derivatives inhibit Factor XIa and plasma kallikrein to treat thrombosis while reducing hereditary angioedema risk.

Segmented implantable depot uses dissolving releasing agent to create diffusion openings, preventing burst release and ensuring sustained drug delivery.

A nanoparticle system uses block copolymers to encapsulate hydrophobic drugs in a stable core.

Carrier-linked prostanoid prodrugs extend therapeutic duration via hydrolytic cleavage, reducing administration frequency for pulmonary hypertension.

Esterifying the carboxylic acid group of cannabidiolic acid creates stable HU-580 derivatives that reduce nausea without thermal degradation.

Compounds of Formula I inhibit ERK kinase activity, addressing insufficient therapeutic efficacy and resistance in cancer treatment.

Sphingosine 1-phosphate receptor modulators and Janus kinase inhibitors reduce gastrointestinal inflammation.

Low GAPDH expression predicts responsiveness to mitochondrial metabolic inhibitors, replacing complex genomic analysis with a simple clinical test.

Phytonutrient compositions protect cells from oxidative stress and genetic damage through antioxidant activity.

Atezolizumab, carboplatin, and etoposide form a combination regimen targeting extensive-stage small cell lung cancer.

A pyrazole-based antioxidant compound stabilizes reactive oxygen species scavenging in water.

Azaindole derivatives block Aurora kinase to induce cell death in tumors while reducing off-target toxicity through selective binding.

Multivesicular liposomes segment tranexamic acid into internal chambers, preventing rapid plasma spikes that cause gastrointestinal side effects.

Modified molecular structures enhance PARP binding affinity to overcome drug resistance in BRCA-mutant cancers.

Room temperature maceration of crushed saffron corms yields water-soluble polysaccharides via ethanol precipitation.

Specific substituent patterns on the imidazo[4,5-c]quinoline core enable blood-brain barrier penetration for treating neurodegenerative diseases.

Solvent migration creates fatty alcohol shells around liquid cores, eliminating tackiness and extending shelf-life.

Probiotic Bacillus strains boost plasma vitamin E levels by 20 to 60 percent, mitigating intestinal dysfunction during the stressful weaning period.

Replacing organic solvents with aqueous dissolution and lyoprotectants eliminates residual toxicity while enabling rapid reconstitution within 15 seconds.

Amphiphilic polymers self-assemble into multi-micellar structures with hydrophilic shells and hydrophobic cores to encapsulate therapeutic agents.

4-amino-5-(4-fluoro-3-phenoxyphenyl)-4H-1,2,4-triazole-3-thiol derivatives inhibit fungal growth to treat infections caused by Candida and Aspergillus species.

Single promoter-driven tandem arrays express multiple crRNAs, reducing vector complexity while degrading viral genomes.

Radiolabeled diazacarbazole compounds cross the blood-brain barrier to detect tau aggregates, replacing invasive biopsy with non-invasive monitoring.

Low-dose rapamycin maintains the senescent state through TOR inhibition and AMPK activation.

GABRA2 gene polymorphisms predict patient weight change during antipsychotic drug treatment.

Dynamic linker units stabilize antibody-camptothecin conjugates during circulation, resolving toxicity risks while maintaining potent anti-tumor activity.

Targeting activating PIK3CA mutations in gynecological cancers using DKK1 inhibitors improves objective response and survival rates.

Administering camostat mesylate inhibits TMPRSS2 to reduce viral load and accelerate symptom resolution in coronavirus infections.

Albumin nanoparticles bind hydrophobic mTOR inhibitors to enable stable subcutaneous administration without toxic surfactants.

A letermovir sodium salt lyophilizate reconstitutes into a clear parenteral solution without complexing solubilizing agents.

Targeting the MSP/RON pathway with specific inhibitors addresses complex tumor-bone interactions, reducing osteolysis independent of RANKL signaling.

A bioabsorbable implant with a sharp tip delivers corticosteroids directly into nasal tissue.

Ritonavir boosts lonafarnib serum concentrations by inhibiting metabolic clearance, enabling significant viral load reduction without high-dose toxicity.

Oral engineered bacteria secrete IL-22 to preserve intestinal stem cells and mitigate irradiation-induced damage.

Formula I compounds inhibit mTOR kinase activity via selective ATP-pocket binding, reducing off-target side effects.

Particulate systems combine caffeine with shellac and release retarding agents to deliver controlled substance release.

Triptan compounds treat organophosphate exposure by targeting serotonin receptors to prevent seizures and long-term neurological damage.

Nitazoxanide inhibits caspase activity to block cytokine-induced apoptosis, addressing organ failure caused by unmanaged inflammatory processes.

Quinazoline derivatives target exon 20 insertion mutations to suppress tumor growth while sparing wild-type EGFR activity.

Replacing palladium acetate with lithium bis(trimethylsilyl)amine resolves cost and stability contradictions in ribociclib succinate production.

2-Pyridyloxy-3-ester-4-ether compounds antagonize orexin receptors, addressing the lack of effective treatments for sleep disorders.

2-Hetarylpyrimidine-4-carboxamide compounds inhibit the Aryl Hydrocarbon Receptor.

Combining cell transplantation with anti-diabetic drugs to resolve glycemic control limits in high-fat environments.

Engineered monoclonal antibody binds Nodal protein to inhibit tumor growth and prevent metastasis in aggressive cancer cells.

Agents modulate GP130 receptor signaling to induce a pluripotency-like state in chondrocytes, priming them for osteoblast differentiation.

Optimizing hyaluronidase dosage alongside collagen stimulators prevents skin sagging while enabling even fat removal.

Combining BChE inhibitors with opioid antagonists addresses limited protection against repeated overdoses by accelerating metabolic clearance.

Flow cytometry quantifies VLA-4 allosteric antagonists by detecting ligand-induced epitopes, resolving assay complexity trade-offs.

Combines a polyunsaturated ketone with a dual PI3K/mTOR inhibitor to enhance therapeutic efficacy.

AntimiR-106b therapy blocks the miR-106b pathway to prevent cardiac damage, reducing mortality from anthracycline-induced cardiotoxicity.

Cannabinoids counteract viral protein interference by inducing interferon transcription and triggering apoptosis in infected host cells.

Pyrimidinyl-heteroaryloxy-naphthyl compounds inhibit IRE1α kinase and endoribonuclease activities to address inadequate cancer therapy coverage.

Wax-based intravaginal devices deliver letrozole via diffusion to maintain prolonged plasma concentrations without consumer health risks.

A topical vasodilator formulation combines arginine with black pepper and peppermint extracts to stimulate blood flow.

A 2,6-disubstituted pyridine derivative stimulates serotonin and dopamine receptors simultaneously.

Liquid crystal molidustat formulations resolve stability and palatability trade-offs to treat feline anemia.

An adeno-associated virus vector delivers a DOK7 gene to reverse neuromuscular junction denervation, restoring muscle strength in aged subjects.

Combining androgen receptor inhibitors with natural killer cell activators targets prostate cancer cells through enhanced immune recognition.

Bisphosphonate-conjugated TGF-beta inhibitors attenuate cartilage degeneration by resolving delivery complexity through local quality.

Thiazolide agents reduce symptom duration and hospitalization rates by inhibiting coronavirus replication.

Screened strains with active histidine operons deliver local histamine to reduce inflammation while avoiding systemic toxicity.

A topical pharmaceutical composition containing a spiro-oxindole compound delivers localized pain relief to affected skin areas.

F127 polymer coating reduces cytotoxicity of butylidenephthalide while treating neurodegenerative diseases and promoting hair growth.

A benzimidazole solubilization method uses water, glycerin, plant oil, and an emulsifier to create a stable pharmaceutical mixture.

Lipid nanoparticle carriers transport chemically modified iRNA agents to the liver, resolving delivery complexity while achieving specific gene silencing.

Combines tyrosine kinase inhibitors with anti-EGF antibodies to delay acquired resistance in non-small-cell lung cancer.

Targeting CK1δ and CK1ε kinases reduces tau hyperphosphorylation, offering a disease-modifying strategy beyond symptomatic relief for Alzheimer's.

A glutaric acid cocrystal modifies the solid state of an IDH1 inhibitor to enable oral pharmaceutical compositions.

Intranasal dantrolene increases brain concentrations by bypassing hepatic metabolism, correcting calcium dysregulation and improving tolerability.

RNA silencing agents target single nucleotide polymorphisms to selectively silence mutant Huntingtin mRNA while sparing normal alleles.

Vacuum microwave drying removes residual solvents from crude rocuronium bromide to meet medicinal purity standards.

GMC1 binds the FKBP52 PPIase pocket to inhibit AR and GR signaling, resolving limitations of single-target therapies.

Pre-treatment with tyrosine kinase inhibitors reduces non-cancerous cell apoptosis during chemotherapy or radiotherapy, minimizing patient side-effects.

Shortened guide RNAs reduce synthesis complexity and degradation while maintaining high gene editing efficiency.

HES-oligonucleotide complexes achieve high-efficiency delivery into cells, reducing required dosage by orders of magnitude.

Lyophilized thrombosomes preserve platelet function across storage conditions.

Chemically modified oligoribonucleotides restore target RNA sequences in living cells, overcoming low efficiency of current gene repair methods.

Antisense oligonucleotides inhibit GluK2/GluK5 receptor expression, addressing refractory epilepsy by reducing epileptiform activity.

High-potency small molecules inhibit MRTF/SRF transcription, reducing toxicity in healthy tissues while treating cancer and fibrosis.

Fused pyrimidine compounds target the allosteric site of PI3Kα to deliver isoform selective kinase inhibition while improving aqueous solubility.

Sf9 cells express the cyclopamine biosynthetic pathway, replacing complex chemical synthesis with a scalable biological production system.

Amide-substituted 4-pyridylamine pyrimidines resolve the contradiction between reliable TGFβ inhibition and sufficient HCV antiviral activity.

Polymer nanocapsules extend blood residence time and minimize immune system disruptions compared to free emulsions.

Functionalized 1,3-benzene diols antagonize GPR55 receptors to mitigate chemotherapy-induced peripheral neuropathy.

ULK1 and ULK2 inhibitors convert cytostatic responses into cytotoxic ones by disrupting autophagy, reducing tumor growth.

Oligonucleotide constructs with modified single guide RNA scaffolds recruit deactivated Cas9 to specific genomic regions.